CTIS2024-511474-68-00招募中1 期
A phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemia
niversitaetsklinikum Tuebingen AöR0 个研究点目标入组 120 人开始时间: 2024年7月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female =18 years of age., Eastern Cooperative Oncology Group [ECOG] < 3., Diagnosis of CLL/SLL established according to iwCLL criteria, Refractory or relapsed CLL that warrants treatment (according to modified criteria for initiation of therapy (Hallek et al., 2018)), CLL relapsing after any line of treatment that included radiotherapy, chemotherapy, immunotherapy, or small molecules. Patients who relapse after a previous therapy with venetoclax can be included in the study in case of a late relapse (i.e. >18 months after venetoclax was discontinued., Discontinuation of all therapy (including radiotherapy, chemotherapy, immunotherapy, or small molecules) for the treatment of CLL =2 weeks before study treatment excluding systemic corticosteroids for symptomatic control., All acute toxic effects of any prior antitumor therapy resolved to Grade =1 before treatment (with the exception of alopecia [Grade 1 or 2 permitted], neurotoxicity [Grade 1 or 2 permitted], or bone marrow parameters [any of Grade 1, 2, 3, or 4 permitted])., Required baseline laboratory data (within 4 weeks prior to treatment), Negative serological Hepatitis B and C test or negative PCR in case of positive serological test without evidence of an active infection, negative HIV test within 6 weeks prior to treatment., Written informed consent of the subject
排除标准
- •(Suspicion of) transformation of CLL (i.e. Richter’s transformation, pro-lymphocytic leukemia) or central nervous system (CNS) involvement, History of prior allogeneic bone marrow or organ transplantation., Ongoing immunosuppressive therapy. Subjects may use topical, enteric, or inhaled corticosteroids as therapy for comorbidities and systemic steroids for autoimmune anemia and/or thrombocytopenia. Ongoing use of low-dose systemic corticosteroids (=5 mg/day of methylprednisolone or equivalent) for rheumatologic conditions is permitted., History of primary immunodeficiency, Concurrent participation in another therapeutic clinical trial., History of serious suicide risk including any suicidal behaviour in the last 6 months, Live vaccination 30 days prior to treatment., Hypersensitivity known from medical history to one of the drugs used or their ingredients or to drugs with a similar chemical structure, Simultaneous participation in another interventional clinical trial (including within the last 4 weeks before inclusion), Addictions or other illnesses that do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences, Pregnant or breastfeeding women, Early relapse (i.e <18 months) after any line of treatment that included venetoclax., Women of childbearing potential, except women who meet the following criteria: A.) post-menopausal (12 months natural amenorrhoea or 6 months amenorrhoea with serum FSH > 40 U/ml) B.) postoperative (6 weeks after bilateral ovarectomy with or without hysterectomy) C.) regular and correct use of a contraceptive method with a Pearl Index < 1% per year, which will have to be continued for up to four months after the discontinuation of the study drug D.) sexual abstinence E.) Vasectomy of the partner, Male subjects who are able to father a child, except men who meet the following criteria: a. willingness to abstain from heterosexual intercourse or use a protocol-recommended method contraception from the screening visit throughout the study treatment period and for four months following the last dose of study drug b. refrain from sperm donation from screening visit throughout the study treatment period and for 90 days following the last dose of study drug., Indications that the subject is unlikely to adhere to the protocol (e.g., lack of compliance), IgG < 4 g/L under substitution of immunoglobulins, Malignancies other than CLL currently requiring systemic therapies, Evidence of active systemic bacterial (e.g. tuberculosis), fungal, or viral infection (e.g., CMV) at the time of initiation of therapy., Confirmed progressive multifocal leukencephalopathy (PML), Known history of drug-induced liver injury (DILI), chronic/active hepatitis C (HCV), chronic/active hepatitis B (HBV)., Requirement of therapy with strong CYP3A4 inhibitors/ inducers or anticoagulant with phenprocoumon (marcumar) or other vitamin Kantagonists, Active inflammatory bowel disease.
研究者
相似试验
进行中（未招募）
1 期
A phase II trial of belimumab in combination withrituximab/venetoclax in patients with refractory orrelapsed chronic lymphocytic leukemiaRefractory or relapsed chronic lymphocytic leukemiaMedDRA version: 21.0Level: LLTClassification code 10009310Term: CLLSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-002622-87-DEniversity Hospital Tuebingen120
招募中
不适用
Phase II trial of pembrolizumab in combination with paclitaxel in the hormone receptor-positive metastatic breast cancer with high tumor mutational burden selected by whole exome sequencing: Korean Cancer Study Group trialKCT0007042Yonsei University Health System, Severance Hospital52
进行中（未招募）
1 期
Phase II trial of Pembrolizumab in combination with Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC)Advanced, Recurrent or Metastatic Endometrial CancerMedDRA version: 12.0 Level: HLGT Classification code 10007129 Term: Cancer-related morbidities System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002824-26-ESVall d' Hebron Institute of Oncology (VHIO)51
招募中
1 期
A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate CancerCTIS2022-501139-17-01Fundación Oncosur42
进行中（未招募）
2 期
A phase 2 study of pembrolizumab in combination with olaparib in patients with cervical cancer previously treated with platinum-based chemotherapyrecurrent or metastatic cervical cancercervical cancer ,Pembrolizumab,OlaparibJPRN-jRCT2031210096Hasegawa Kosei28